uniQure
QURE · Nasdaq · Netherlands
Share price · QURE
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when QURE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 29 Sep 2026-37.3%
- 24 Sep 2026-10.4%
Nothing announced by QURE that day or the session before.
- 17 Jun 2026+78.4%
- 9 Mar 2026+26.1%
Nothing announced by QURE that day or the session before.
- 6 Mar 2026+34.0%
Nothing announced by QURE that day or the session before.
- 5 Mar 2026+17.8%
Nothing announced by QURE that day or the session before.
- 2 Mar 2026-32.8%
- 26 Feb 2026-31.2%
Nothing announced by QURE that day or the session before.
- 3 Feb 2026+12.6%
Nothing announced by QURE that day or the session before.
Share of unusual movement by asset
For each asset, the share of QURE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
etranacogene dezaparvovec(Hemgenix) | Approved | Factor IX gene delivery (hFIX-Padua)Gene therapy / editing | Hemophilia B |
| Phase 1/2 | GRIK2 (GluK2-containing kainate receptor)Gene therapy / editing | Epilepsy | |
| Phase 1/2 | Huntingtin (HTT) geneGene therapy / editing | Huntington's Disease |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $5.2M | $36M | $100M+ $570M short-term inv. | $61M-$48M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $5.8M | $34M | $415M+ $397M short-term inv. | $81M-$29M operating cash flow | report ↗ |
| 2026-Q1 | — | $29M | $142M+ $447M short-term inv. | $54M-$38M operating cash flow | report ↗ |
| 2025-Q3 | $3.7M | $34M | $599M+ $97M short-term inv. | $81M-$16M operating cash flow | report ↗ |
| 2025-Q2 | $5.3M | $35M | $255M+ $123M short-term inv. | $38M-$40M operating cash flow | report ↗ |
| 2025-Q1 | $1.6M | $36M | $219M+ $192M short-term inv. | $44M-$44M operating cash flow | report ↗ |
| 2024-Q3 | $2.3M | $31M | $253M+ $184M short-term inv. | $44M-$37M operating cash flow | report ↗ |
| 2024-Q2 | $11M | $34M | $291M+ $237M short-term inv. | $56M-$33M operating cash flow | report ↗ |
| 2024-Q1 | $8.5M | $41M | $246M+ $313M short-term inv. | —-$61M operating cash flow | report ↗ |
| 2023-Q3 | $1.4M | $65M | $233M+ $429M short-term inv. | —$39M operating cash flow | report ↗ |
| 2023-Q2 | $2.4M | $46M | $517M+ $115M short-term inv. | —-$57M operating cash flow | report ↗ |
| 2023-Q1 | $5.3M | $61M | $157M+ $161M short-term inv. | —-$78M operating cash flow | report ↗ |
| 2022-Q3 | $1.4M | $48M | $443M | —-$49M operating cash flow | report ↗ |
| 2022-Q2 | $0.5M | $46M | $504M | —-$16M operating cash flow | report ↗ |
| 2022-Q1 | $1.8M | $45M | $528M | —-$26M operating cash flow | report ↗ |
| 2021-Q3 | $2.0M | $36M | $581M | —-$40M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $16M | $141M | $82M+ $543M short-term inv. | $50M-$178M operating cash flow | report ↗ |
uniQure reported FY2025 revenue of $16.1M, down 40.6% YoY, with R&D expense of $140.67M, down 2.2% YoY. The company ended the period with cash and equivalents of $81.8M, or approximately $622.5M including current investment securities, and reported a net loss of $198.97M ($3.46 diluted loss per ordinary share).
Management expects existing cash, cash equivalents, and investment securities to fund operations into the second half of 2029. On the pipeline, the FDA stated in a Type A meeting that AMT-130 Phase I/II data with an external control are not sufficient to support a marketing application and recommended a prospective, randomized, double-blind, sham-surgery-controlled study; uniQure plans to request a Type B meeting in Q2 2026. AMT-260 completed first-cohort enrollment with a second cohort underway and data expected in Q2 2026. AMT-191 showed durable, dose-dependent enzyme activity increases, though dosing in mid- and high-dose cohorts was paused after Grade 3 liver enzyme elevations, and AMT-162 enrollment remains on voluntary pause.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $27M | $144M | $160M+ $209M short-term inv. | $60M-$183M operating cash flow | report ↗ |
| 2023-FY | $16M | $215M | $245M+ $377M short-term inv. | $77M-$146M operating cash flow | report ↗ |
| 2022-FY | $106M | $198M | $231M+ $125M short-term inv. | $32M-$145M operating cash flow | report ↗ |
| 2021-FY | $524M | $144M | $559M | —$288M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 53 sales ($20.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-06 | Meek David D. · director | Open-market sale | 9,080 | $21.25 | $193K | Form 4 |
| 2026-10-30 | Abi-Saab Walid · Chief Medical Officer | Award / grant | 18,750 | — | — | Form 4 |
| 2026-07-02 | Kapusta Matthew C · director, CEO, Managing Director | Option exercise | 21,082 | $19.39 | $409K | Form 4 |
| 2026-07-02 | Kapusta Matthew C · director, CEO, Managing Director | Open-market sale | 9,200 | $44.43 | $409K | Form 4 |
| 2026-07-02 | Kapusta Matthew C · director, CEO, Managing Director | Open-market sale | 4,282 | $45.43 | $195K | Form 4 |
| 2026-07-02 | Kapusta Matthew C · director, CEO, Managing Director | Open-market sale | 7,600 | $45.89 | $349K | Form 4 |
| 2026-07-02 | Kapusta Matthew C · director, CEO, Managing Director | Option exercise (derivative) | 21,082 | — | — | Form 4 |
| 2026-06-30 | Kaye Jack · director | Option exercise | 4,107 | $37.00 | $152K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 211 reporting institutions held 60.0M shares ($961.1M, 95.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Avoro Capital Advisors LLC | 5,959,595 | $97.4M |
| 2 | Aberdeen Group plc | 5,306,386 | $86.8M |
| 3 | TWO SIGMA INVESTMENTS, LP | 2,675,871 | $43.8M |
| 4 | RTW INVESTMENTS, LP | 2,586,356 | $42.3M |
| 5 | JPMORGAN CHASE & CO | 2,837,466 | $41.8M |
| 6 | STATE STREET CORP | 2,260,512 | $37.0M |
| 7 | ORBIMED ADVISORS LLC | 2,136,149 | $34.9M |
| 8 | FMR LLC | 1,743,808 | $28.5M |
| 9 | BlackRock, Inc. | 1,733,458 | $28.3M |
| 10 | MPM BIOIMPACT LLC | 1,369,231 | $22.4M |
| 11 | Two Seas Capital LP | 1,300,000 | $21.3M |
| 12 | GOLDMAN SACHS GROUP INC | 1,263,236 | $20.7M |
| 13 | JENNISON ASSOCIATES LLC | 1,233,789 | $20.2M |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,002,800 | $16.4M |
| 15 | Siren, L.L.C. | 1,000,000 | $16.4M |